Secarna Pharmaceuticals GmbH & Co. KG, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, expanded its research collaboration and option agreement with Denali Therapeutics Inc. in the field of neurodegenerative diseases. The companies also added multiple additional discovery and research programs across a range of indications to the partnership.   Secar...